NSAIDs Treatment in Children With Pleuropneumonia

Not Applicable

• Conditions: Pleuro-pneumonia
• Interventions: Drug: Acetaminophen; Drug: Ibuprofen

• Registration Number: NCT01586299
• Lead Sponsor: Rabin Medical Center

Brief Summary

The purpose of this study is to evaluate the influence of routine NSAIDs treatment for hospitalized children with pleuropneumonia in comparison with acetominophen treatment (all in conjunction with adequate antibiotic therapy).

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-01
• Study Start: 2012-03
• Study First Submitted: 2012-03-19
• Study First Submitted QC: 2012-04-25
• Study First Posted: 2012-04-26
• Last Update Submitted: 2014-11-13
• Last Update Posted: 2014-11-14
• Primary Completion: 2015-06
• Study Completion: 2015-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• age less than 18 years
• admission in Schneider childrenMC of Israel, wards a/c
• clinical diagnosis of pneumonia with evidence of pleural effusion on chest X-ray
• parental informed consent
• follow-up ability after discharge

Exclusion Criteria

• pneumonia secondary to foreign body aspiration
• immune deficiency
• chronic lung disease other than asthma (CF, CLD of prematurity, Familial Dysautonomia, etc)
• significant premorbidity (organ failure, rheumatic disease, etc)
• endotracheal/endobronchial devices including tracheostomy.
• parental refusal to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
acetaminophen	Acetaminophen	-
ibuprofen	Ibuprofen	-

Primary Outcome Measures

Name	Time	Method
clinical improvement as manifested by resolution of fever and length of hospital admission.	participants will be followed for the duration of hospital stay, an expected average of 10 days

Secondary Outcome Measures

Name	Time	Method
clinical improvement as manifested by respiratory parameters (tachypnea, dyspnea, Fio2),and inflammatory markers.	participants will be followed for the duration of hospital stay, an expected average of 10 days

Trial Locations

Locations (1)

Schneider's medical center of Israel; 🇮🇱 Petah Tikva, Israel